TD Asset Management
KNTE

TD Asset Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

TD Asset Management’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-37,407
Closed -$807K – 1561
2021
Q2 		$807K Sell
37,407
-7,300
-16% -$186K ﹤0.01% 1302
2021
Q1 		$1.39M Buy
44,707
+6,421
+17% +$224K ﹤0.01% 1194
2020
Q4 		$1.52M Buy
+38,286
New +$1.54M ﹤0.01% 1096

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TD Asset Management's KNTE Position: Q3 2021 in Review

TD Asset Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2021, closing a stake of 37,407 shares — an estimated $807K sold.

TD Asset Management first reported a position in KNTE in Q4 2020 and held it in 3 quarters. The position peaked at $1.52M in Q4 2020. 73 funds tracked by Wall St. Rank hold KNTE as of Q3 2021.

  • TD Asset Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • TD Asset Management sold 37,407 Kinnate Biopharma Inc. Common Stock shares in Q3 2021, an estimated $807K.
  • TD Asset Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • TD Asset Management's Kinnate Biopharma Inc. Common Stock position peaked at $1.52M in Q4 2020.
  • 73 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2021.

Based on TD Asset Management's 13F filing for Q3 2021, filed 9 Nov 2021.